Symptom Management

SGX942 Decreases Duration of Severe Oral Mucositis in Patients with Head and Neck Cancer

Meg Barbor, MPH

November 2016, Vol 7, No 10 - Symptom Management

Adelaide, Australia—SGX942, a novel agent that is first in its class, decreased the incidence of severe oral mucositis in patients with head and neck cancer undergoing chemoradiation, according to new research led by Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer, Soligenix, Princeton, NJ, and Mahesh R. Kudrimoti, MD, Professor of Radiation Medicine, University of Kentucky, Lexington. [ Read More ]

Managing Delirium in Patients with Cancer

Meg Barbor, MPH

November 2016, Vol 7, No 10 - Symptom Management

Delirium is an exceedingly prevalent syndrome among patients with cancer, but is underrecognized and undertreated, according to Alan Valentine, MD, Chair, Department of Psychiatry, The University of Texas M.D. Anderson Cancer Center, Houston, and Darryl Etter, PsyD, Clinical Psychologist, VA Eastern Colorado Health Care System, Denver, at a webinar hosted by the American Psychosocial Oncology Society in July 2016. [ Read More ]